JP2008189637A - 自己免疫疾患予防剤 - Google Patents
自己免疫疾患予防剤 Download PDFInfo
- Publication number
- JP2008189637A JP2008189637A JP2007028809A JP2007028809A JP2008189637A JP 2008189637 A JP2008189637 A JP 2008189637A JP 2007028809 A JP2007028809 A JP 2007028809A JP 2007028809 A JP2007028809 A JP 2007028809A JP 2008189637 A JP2008189637 A JP 2008189637A
- Authority
- JP
- Japan
- Prior art keywords
- milk
- autoimmune disease
- basic protein
- lactoperoxidase
- lactoferrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000023275 Autoimmune disease Diseases 0.000 title claims abstract description 54
- 230000000069 prophylactic effect Effects 0.000 title 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 claims abstract description 44
- 102000010445 Lactoferrin Human genes 0.000 claims abstract description 30
- 108010063045 Lactoferrin Proteins 0.000 claims abstract description 30
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims abstract description 30
- 229940078795 lactoferrin Drugs 0.000 claims abstract description 30
- 235000021242 lactoferrin Nutrition 0.000 claims abstract description 30
- 108010023244 Lactoperoxidase Proteins 0.000 claims abstract description 29
- 102000045576 Lactoperoxidases Human genes 0.000 claims abstract description 29
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims abstract description 29
- 229940057428 lactoperoxidase Drugs 0.000 claims abstract description 29
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 22
- 235000013336 milk Nutrition 0.000 claims description 45
- 239000008267 milk Substances 0.000 claims description 45
- 210000004080 milk Anatomy 0.000 claims description 45
- 230000002554 disease preventive effect Effects 0.000 claims description 23
- 239000004480 active ingredient Substances 0.000 claims description 14
- 230000003449 preventive effect Effects 0.000 claims description 5
- 238000007796 conventional method Methods 0.000 abstract description 9
- 230000003405 preventing effect Effects 0.000 abstract description 6
- 239000000463 material Substances 0.000 abstract description 2
- 230000007774 longterm Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 28
- 239000003795 chemical substances by application Substances 0.000 description 20
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 13
- 238000000034 method Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- 230000008961 swelling Effects 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000000427 antigen Substances 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 239000008367 deionised water Substances 0.000 description 8
- 229910021641 deionized water Inorganic materials 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 235000012054 meals Nutrition 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 230000006472 autoimmune response Effects 0.000 description 6
- 230000005784 autoimmunity Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 101150086609 groEL2 gene Proteins 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- 229920001661 Chitosan Polymers 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108010073771 Soybean Proteins Proteins 0.000 description 3
- 235000010724 Wisteria floribunda Nutrition 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003729 cation exchange resin Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 210000003289 regulatory T cell Anatomy 0.000 description 3
- 229940001941 soy protein Drugs 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- 102000006303 Chaperonin 60 Human genes 0.000 description 2
- 108010058432 Chaperonin 60 Proteins 0.000 description 2
- 241000725101 Clea Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 101000883686 Homo sapiens 60 kDa heat shock protein, mitochondrial Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000000521 Immunophilins Human genes 0.000 description 2
- 108010016648 Immunophilins Proteins 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 239000012505 Superdex™ Substances 0.000 description 2
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- -1 ester compounds Chemical class 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 102000046432 human HSPD1 Human genes 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 235000000891 standard diet Nutrition 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000030767 Autoimmune encephalitis Diseases 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000004631 Calcineurin Human genes 0.000 description 1
- 108010042955 Calcineurin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010024212 E-Selectin Proteins 0.000 description 1
- 102100023471 E-selectin Human genes 0.000 description 1
- 241000611421 Elia Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920001543 Laminarin Polymers 0.000 description 1
- 239000005717 Laminarin Substances 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000186366 Mycobacterium bovis Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003460 anti-nuclear Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000013377 clone selection method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000001280 germinal center Anatomy 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 230000002134 immunopathologic effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 102000027411 intracellular receptors Human genes 0.000 description 1
- 108091008582 intracellular receptors Proteins 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000006277 sulfonation reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000021195 test diet Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 210000003857 wrist joint Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
- C12Y111/01—Peroxidases (1.11.1)
- C12Y111/01007—Peroxidase (1.11.1.7), i.e. horseradish-peroxidase
Abstract
【解決手段】乳由来の塩基性タンパク質画分、ラクトパーオキシダーゼ、及びラクトフェリンを経口的に摂取することにより、従来の方法では有効に予防あるいは治療できなかった1型糖尿病や関節リウマチ等の自己免疫疾患を予防することができる。
【選択図】 なし
Description
すなわち、本発明は、乳由来の塩基性タンパク質画分を有効成分とする自己免疫疾患予防剤に関するものである。また、乳由来塩基性タンパク質が、ラクトパーオキシダーゼ及び/又はラクトフェリンである自己免疫疾患予防剤である。また、乳由来の塩基性タンパク質画分、ラクトパーオキシダーゼ及び/又はラクトフェリンを有効成分とし、自己免疫疾患が1型糖尿病又は関節リウマチであることを特徴とする自己免疫疾患予防剤である。本発明による乳由来の塩基性タンパク質画分、ラクトパーオキシダーゼ、及びラクトフェリンを経口的に摂取することにより、従来の方法では有効に予防あるいは治療できなかった1型糖尿病や関節リウマチ等の自己免疫疾患を予防することができる。
1) ソジウムドデシルサルフェート−ポリアクリルアミドゲル電気泳動(SDS-PAGE)によると分子量 3,000〜80,000の範囲の数種のタンパク質よりなる。
2) 95重量%以上がタンパク質であって、その他少量の脂肪、灰分を含む。
3) タンパク質は主としてラクトフェリン及びラクトパーオキシダーゼよりなる。
4) タンパク質のアミノ酸組成は、リジン、ヒスチジン、アルギニン等の塩基性アミノ酸を15重量%以上含有する。
実施例1で得られた乳由来の塩基性タンパク質画分について、ソジウムドデシルサルフェート−ポリアクリルアミドゲル電気泳動(SDS-PAGE)により測定したところ、分子量は 3,000〜80,000の範囲に分布していた。
実施例1で得られた乳由来の塩基性タンパク質画分について、成分組成を分析した。その結果を表1に示す。この表に示すとおり、この画分のほとんどはタンパク質である。
───────────────────
水分 1.06 (重量%)
タンパク質 96.5
脂肪 0.56
灰分 0.27
その他 1.61
───────────────────
実施例1で得られた乳由来の塩基性タンパク質画分について、6N塩酸で 110℃、24時間加水分解した後、アミノ酸分析装置(L-8500型、日立製作所製) でそのアミノ酸組成を分析した。その結果を表2に示す。この乳由来の塩基性タンパク質画分には、アミノ酸組成中15重量%以上の塩基性アミノ酸が含まれている。
──────────────────────
アスパラギン酸 10.1 (重量%)
セリン 5.3
グルタミン酸 12.3
プロリン 4.7
アラニン 5.7
ロイシン 10.2
リジン 8.4
ヒスチジン 2.6
アルギニン 7.2
その他 33.5
─────────────────────
(インスリン依存性糖尿病の発症を誘導する自己免疫疾患の発症抑制効果)
1型糖尿病モデル(NOD)マウスを用いて、乳由来の塩基性タンパク質画分、ラクトフェリン及びラクトパーオキシダーゼの、インスリン依存性糖尿病の発症を誘導する自己免疫応答に対する抑制効果を検討した。
NODマウス(日本クレア、4週齢)を一般配合飼料MF食(オリエンタル酵母工業社製)で1週間飼育した後、4群(7匹ずつ)に分け、対照群(MF標準食)、試験群T(MF食に実施例1で得られた乳由来の塩基性タンパク質画分を0.1%配合した試験食)、試験群LP(MF食に実施例2で得られたラクトパーオキシダーゼを0.1%配合した試験食)及び試験群LF(MF食に実施例3で得られた0.1%ラクトフェリンを配合した試験食)で飼育した。38日間飼育した10週齢時に、一群あたり7匹を用いて、尿中の糖濃度を測定して、尿中ブドウ糖値が正常値である20mg/dlを基準値とし、これを超えるものを陽性とした。尿中の糖濃度を測定して、糖尿病が発症するかどうか確認した結果を表3に示す。
尿糖値陽性数(個体数/全数)
─────────────────────────
対照群 7/7
試験群T 1/7
試験群LP 0/7
試験群LF 5/7
────────────────────────
(腫脹発症を誘導する自己免疫疾患の発症抑制効果)
自然発症型関節リウマチモデル(SKG)マウスを用いて、乳塩基性タンパク質画分、ラクトフェリン及びラクトパーオキシダーゼの、腫脹発症を誘導する自己免疫応答に対する抑制効果を検討した。
自然発症性関節リウマチモデル(SKG)マウス(日本クレア、4週齢)を一般配合飼料MF食(オリエンタル酵母工業社製)で1週間飼育した後、4群(5匹ずつ)に分け、対照群(MF標準食)、試験群T(MF食に実施例1で得られた乳塩基性タンパク質画分を0.1%配合した試験食)、試験群LP(MF食に実施例2で得られたラクトパーオキシダーゼを0.1%配合した試験食)及び試験群LF(MF食に実施例3で得られたラクトフェリンを0.1%配合した試験食)で飼育した。38日間飼育した10週齢時に、ラミナリン(シグマ社製L9634)を腹腔投与した後の関節リウマチの発症頻度を測定した。関節リウマチの発症の評価は、指間骨関節の腫脹1ヶ所について0.1、手関節、足関節の中等度の腫脹を0.5、高度の腫脹を1.0としたスコアにより行った。腫脹を測定して、1個体あたりの平均腫脹スコアを求めて関節リウマチの発症頻度を確認した結果を表4に示す。
平均腫脹スコア(1個体あたり)
─────────────────────────
対照群 4.6±1.4
試験群T 1.8±0.4
試験群LP 1.1±0.6
試験群LF 1.5±0.9
────────────────────────
────────────────────────────
含水結晶ブドウ糖 81.1 (重量%)
大豆タンパク質 12
ミネラル混合 5
シュガーエステル 1
香料 0.5
塩基性タンパク質画分粉末(実施例1) 0.4
────────────────────────────
─────────────────────────────
含水結晶ブドウ糖 80.3 (重量%)
大豆タンパク質 13
ミネラル混合 5
シュガーエステル 1
香料 0.5
ラクトパーオキシダーゼ粉末(実施例2) 0.2
────────────────────────────
────────────────────────────
含水結晶ブドウ糖 80.3 (重量%)
大豆タンパク質 13
ミネラル混合 5
シュガーエステル 1
香料 0.5
ラクトフェリン粉末(実施例3) 0.2
────────────────────────────
Claims (6)
- 乳由来の塩基性タンパク質画分を有効成分とする自己免疫疾患予防剤。
- 乳由来の塩基性タンパク質がラクトパーオキシダーゼ及び/又はラクトフェリンであることを特徴とする請求項1記載の自己免疫疾患予防剤。
- 乳由来の塩基性タンパク質画分を有効成分とし、自己免疫疾患が1型糖尿病であることを特徴とする自己免疫疾患予防剤。
- 乳由来の塩基性タンパク質がラクトパーオキシダーゼである、請求項3記載の自己免疫疾患が1型糖尿病であることを特徴とする自己免疫疾患予防剤。
- 乳由来の塩基性タンパク質画分を有効成分とし、自己免疫疾患が関節リウマチであることを特徴とする自己免疫疾患予防剤。
- 乳由来の塩基性タンパク質がラクトパーオキシダーゼ及び/又はラクトフェリンである、請求項5記載の自己免疫疾患が関節リウマチであることを特徴とする自己免疫疾患予防剤。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007028809A JP2008189637A (ja) | 2007-02-08 | 2007-02-08 | 自己免疫疾患予防剤 |
EP08710936A EP2119445A4 (en) | 2007-02-08 | 2008-02-07 | PROPHYLACTIC AGENT FOR AUTOIMMUNE DISEASE |
US12/525,882 US20100316621A1 (en) | 2007-02-08 | 2008-02-07 | Prophylatic agent for autoimmune disease |
CN2008800042933A CN101631555B (zh) | 2007-02-08 | 2008-02-07 | 自身免疫病预防剂 |
PCT/JP2008/052057 WO2008096826A1 (ja) | 2007-02-08 | 2008-02-07 | 自己免疫疾患予防剤 |
CA002677233A CA2677233A1 (en) | 2007-02-08 | 2008-02-07 | Prophylactic agent for autoimmune disease |
AU2008212212A AU2008212212A1 (en) | 2007-02-08 | 2008-02-07 | Prophylactic agent for autoimmune disease |
KR1020097017223A KR20090108088A (ko) | 2007-02-08 | 2008-02-07 | 자기면역질환 예방제 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007028809A JP2008189637A (ja) | 2007-02-08 | 2007-02-08 | 自己免疫疾患予防剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2008189637A true JP2008189637A (ja) | 2008-08-21 |
Family
ID=39681730
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007028809A Pending JP2008189637A (ja) | 2007-02-08 | 2007-02-08 | 自己免疫疾患予防剤 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20100316621A1 (ja) |
EP (1) | EP2119445A4 (ja) |
JP (1) | JP2008189637A (ja) |
KR (1) | KR20090108088A (ja) |
CN (1) | CN101631555B (ja) |
AU (1) | AU2008212212A1 (ja) |
CA (1) | CA2677233A1 (ja) |
WO (1) | WO2008096826A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014168253A1 (ja) | 2013-04-09 | 2014-10-16 | 国立大学法人東京大学 | 白血球の細胞外トラップ形成の阻害剤 |
JP2017137266A (ja) * | 2016-02-04 | 2017-08-10 | 雪印メグミルク株式会社 | 軟骨機能改善剤 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI589299B (zh) | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
KR101583734B1 (ko) | 2014-09-01 | 2016-01-08 | 강원대학교 산학협력단 | 락토페린 및 레티노산을 함유하는 면역질환 예방 또는 치료용 조성물 |
JPWO2016056665A1 (ja) * | 2014-10-08 | 2017-08-10 | 学校法人慶應義塾 | 白血球の細胞外トラップ形成の阻害剤 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05186368A (ja) * | 1992-01-08 | 1993-07-27 | Santen Pharmaceut Co Ltd | 抗リウマチ剤 |
JPH08151331A (ja) * | 1994-09-30 | 1996-06-11 | Snow Brand Milk Prod Co Ltd | 骨強化剤 |
JPH10279479A (ja) * | 1997-04-04 | 1998-10-20 | Sagami Chem Res Center | インターロイキン6の生産抑制剤 |
WO2004073733A1 (ja) * | 2003-02-24 | 2004-09-02 | Morinaga Milk Industry Co., Ltd. | インターロイキン−6産生抑制剤 |
WO2004103285A2 (en) * | 2003-05-14 | 2004-12-02 | Agennix Incorporated | Lactoferrin in the treatment of diabetes mellitus |
US20060040025A1 (en) * | 2002-07-02 | 2006-02-23 | Jerome Souppe | Milk protein isolate and method for preparing same |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE901672A (fr) | 1985-02-07 | 1985-08-07 | Oleofina Sa | Procede de purification de proteines du lait et de ses derives. |
US5268170A (en) | 1986-09-09 | 1993-12-07 | Yeda Research And Development Co., Ltd. | Methods of treatment and diagnosis of autoimmune diseases, especially arthritic conditions |
JPH0725800B2 (ja) | 1987-04-10 | 1995-03-22 | 雪印乳業株式会社 | 硫酸エステル化物を用いて乳からラクトフエリンを分離、精製する方法 |
FR2616628B1 (fr) | 1987-06-19 | 1989-09-29 | Entremont Sa | Procede pour extraire des proteines du lactoserum par adsorption et elution |
NL8703107A (nl) | 1987-12-22 | 1989-07-17 | Nederlanden Staat | Polypeptiden en derivaten daarvan, alsmede de toepassing daarvan in farmaceutische en diagnostische preparaten. |
US5578303A (en) | 1989-03-14 | 1996-11-26 | Yeda Research And Development Co. Ltd. | Diagnosis and treatment of insulin dependent diabetes mellitus |
JP2686831B2 (ja) | 1989-09-22 | 1997-12-08 | 雪印乳業株式会社 | 鉄結合性蛋白質を分離、精製し、採取する方法 |
JPH05202098A (ja) | 1992-01-29 | 1993-08-10 | Snow Brand Milk Prod Co Ltd | 乳質原料から生理活性物質の製造法 |
GB9312369D0 (en) * | 1993-06-16 | 1993-07-28 | Sandoz Nutrition Ltd | Organic compounds |
US5747470A (en) * | 1995-06-07 | 1998-05-05 | Gen-Probe Incorporated | Method for inhibiting cellular proliferation using antisense oligonucleotides to gp130 mRNA |
KR19990022359A (ko) * | 1995-06-07 | 1999-03-25 | 다니엘 엘. 캐시앙, 헨리 엘. 노르호프 | 시토킨 시그날 트랜스듀서 gp130 mRNA에 특이적인 올리고뉴클레오티드 |
US5674995A (en) * | 1995-06-07 | 1997-10-07 | Gen-Probe Incorporated | Oligonucleotides specific for cytokine signal transducer gp130 mRNA |
NL1005037C2 (nl) * | 1997-01-17 | 1998-07-20 | Nl Zuivelonderzoek Inst | Werkwijze voor het selectief afbreken van melkeiwit, in het bijzonder voor het selectief hydrolyseren van caseïne/caseïnaat in aanwezigheid van andere melkeiwitten, in het bijzonder wei-eiwitten. |
CN1114618C (zh) * | 2000-05-19 | 2003-07-16 | 程伶辉 | 三价铬复合物、其乳制品及其制造方法 |
CN100528223C (zh) * | 2003-05-07 | 2009-08-19 | 雪印乳业株式会社 | 皮肤胶原产生促进剂 |
US20080221023A1 (en) * | 2004-05-27 | 2008-09-11 | Campina Nederland Holding | Use of Protein Hydrolysates For the Manufacture of a Medicament For Prophylaxis and/or Treatment of a Dpp-IV Mediated Condition |
EP1831361B1 (en) * | 2004-12-23 | 2012-01-25 | Campina Nederland Holding B.V. | Protein hydrolysate enriched in peptides inhibiting dpp-iv and their use |
FR2889068B1 (fr) * | 2005-07-29 | 2012-03-02 | Cie Laitiere Europeenne | Nouvelles fractions proteiques laitieres et leur utilisation pour la prevention ou le traitement des maladies inflammatoires chroniques |
DK1800675T3 (da) * | 2005-12-23 | 2011-09-05 | Nutricia Nv | Sammensætninger omfattende polyumættede fedtsyrer, proteiner og mangan og/eller molybdæn og nucleosider/nucleotider til behandling af demens |
WO2007103525A2 (en) * | 2006-03-09 | 2007-09-13 | Glanbia Nutritionals (Ireland) Limited | Cationic whey protein composition |
-
2007
- 2007-02-08 JP JP2007028809A patent/JP2008189637A/ja active Pending
-
2008
- 2008-02-07 WO PCT/JP2008/052057 patent/WO2008096826A1/ja active Application Filing
- 2008-02-07 KR KR1020097017223A patent/KR20090108088A/ko not_active Application Discontinuation
- 2008-02-07 CN CN2008800042933A patent/CN101631555B/zh not_active Expired - Fee Related
- 2008-02-07 US US12/525,882 patent/US20100316621A1/en not_active Abandoned
- 2008-02-07 EP EP08710936A patent/EP2119445A4/en not_active Withdrawn
- 2008-02-07 CA CA002677233A patent/CA2677233A1/en not_active Abandoned
- 2008-02-07 AU AU2008212212A patent/AU2008212212A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05186368A (ja) * | 1992-01-08 | 1993-07-27 | Santen Pharmaceut Co Ltd | 抗リウマチ剤 |
JPH08151331A (ja) * | 1994-09-30 | 1996-06-11 | Snow Brand Milk Prod Co Ltd | 骨強化剤 |
JPH10279479A (ja) * | 1997-04-04 | 1998-10-20 | Sagami Chem Res Center | インターロイキン6の生産抑制剤 |
US20060040025A1 (en) * | 2002-07-02 | 2006-02-23 | Jerome Souppe | Milk protein isolate and method for preparing same |
WO2004073733A1 (ja) * | 2003-02-24 | 2004-09-02 | Morinaga Milk Industry Co., Ltd. | インターロイキン−6産生抑制剤 |
WO2004103285A2 (en) * | 2003-05-14 | 2004-12-02 | Agennix Incorporated | Lactoferrin in the treatment of diabetes mellitus |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014168253A1 (ja) | 2013-04-09 | 2014-10-16 | 国立大学法人東京大学 | 白血球の細胞外トラップ形成の阻害剤 |
JP2017137266A (ja) * | 2016-02-04 | 2017-08-10 | 雪印メグミルク株式会社 | 軟骨機能改善剤 |
JP2021121591A (ja) * | 2016-02-04 | 2021-08-26 | 雪印メグミルク株式会社 | 軟骨機能改善剤 |
Also Published As
Publication number | Publication date |
---|---|
KR20090108088A (ko) | 2009-10-14 |
CN101631555B (zh) | 2013-04-03 |
CN101631555A (zh) | 2010-01-20 |
CA2677233A1 (en) | 2008-08-14 |
WO2008096826A1 (ja) | 2008-08-14 |
US20100316621A1 (en) | 2010-12-16 |
AU2008212212A1 (en) | 2008-08-14 |
EP2119445A1 (en) | 2009-11-18 |
EP2119445A4 (en) | 2012-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2635444B2 (ja) | 自己抗体の経口投与による自己免疫性疾患の治療 | |
US10570468B2 (en) | Crystallized oxalate decarboxylase and methods of use | |
US10363306B2 (en) | Cytokines and neuroantigens for treatment of immune disorders | |
Nicholas et al. | Autoantigen based vaccines for type 1 diabetes | |
AU2005207891B2 (en) | Hsp therapy in conjunction with a low antigenicity diet | |
JP2008189637A (ja) | 自己免疫疾患予防剤 | |
JP2004026797A (ja) | ペプチドp277類似体及びこれを含む糖尿病の治療又は診断のための薬剤組成物 | |
US20020119159A1 (en) | Combinations of antigen and mucosal binding component for inducing specific immunological tolerance | |
WO2021231898A2 (en) | Nanoparticle compositions and uses thereof | |
JP7419229B2 (ja) | 方法 | |
JP5272115B2 (ja) | 経口免疫寛容を誘導するペプチド組成物及びその製造方法 | |
WO2019067087A1 (en) | GEMELLA SANGUINIS AS BIOTHERAPEUTIC AGENTS | |
JP4149713B2 (ja) | 感染症治療剤 | |
US10940200B2 (en) | Aluminum based adjuvants for tolerogenic vaccination | |
HRP20040071A2 (en) | Use of il-18 inhibitors in hypersensitivity disorders | |
KR101917419B1 (ko) | Crif1을 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 조성물 | |
JP5598504B2 (ja) | 経口免疫寛容を誘導するペプチド組成物及びその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100129 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20110725 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110728 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120726 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130129 |